CN111011522A - Children formula milk powder capable of improving immunity and preparation method thereof - Google Patents
Children formula milk powder capable of improving immunity and preparation method thereof Download PDFInfo
- Publication number
- CN111011522A CN111011522A CN202010122634.XA CN202010122634A CN111011522A CN 111011522 A CN111011522 A CN 111011522A CN 202010122634 A CN202010122634 A CN 202010122634A CN 111011522 A CN111011522 A CN 111011522A
- Authority
- CN
- China
- Prior art keywords
- powder
- children
- milk powder
- parts
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000843 powder Substances 0.000 title claims abstract description 157
- 235000013350 formula milk Nutrition 0.000 title claims abstract description 46
- 230000036039 immunity Effects 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title description 9
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims abstract description 36
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 32
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 24
- 229940088594 vitamin Drugs 0.000 claims abstract description 23
- 229930003231 vitamin Natural products 0.000 claims abstract description 23
- 235000013343 vitamin Nutrition 0.000 claims abstract description 23
- 239000011782 vitamin Substances 0.000 claims abstract description 23
- 150000001875 compounds Chemical class 0.000 claims abstract description 22
- 235000013336 milk Nutrition 0.000 claims abstract description 21
- 239000008267 milk Substances 0.000 claims abstract description 21
- 210000004080 milk Anatomy 0.000 claims abstract description 21
- 102000010445 Lactoferrin Human genes 0.000 claims abstract description 19
- 108010063045 Lactoferrin Proteins 0.000 claims abstract description 19
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 19
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims abstract description 19
- 229940078795 lactoferrin Drugs 0.000 claims abstract description 19
- 235000021242 lactoferrin Nutrition 0.000 claims abstract description 19
- 239000011707 mineral Substances 0.000 claims abstract description 19
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 19
- 239000008158 vegetable oil Substances 0.000 claims abstract description 19
- 229940090949 docosahexaenoic acid Drugs 0.000 claims abstract description 18
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 18
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 17
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 17
- 235000021119 whey protein Nutrition 0.000 claims abstract description 17
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 claims abstract description 16
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229960003080 taurine Drugs 0.000 claims abstract description 16
- 241000283690 Bos taurus Species 0.000 claims abstract description 15
- 210000003022 colostrum Anatomy 0.000 claims abstract description 15
- 235000021277 colostrum Nutrition 0.000 claims abstract description 15
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims abstract description 15
- 229940107187 fructooligosaccharide Drugs 0.000 claims abstract description 15
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims abstract description 12
- 235000019743 Choline chloride Nutrition 0.000 claims abstract description 12
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 12
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 12
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims abstract description 12
- 229960003178 choline chloride Drugs 0.000 claims abstract description 12
- -1 compound vitamin Chemical class 0.000 claims abstract description 12
- 239000008101 lactose Substances 0.000 claims abstract description 12
- 235000016709 nutrition Nutrition 0.000 claims abstract description 12
- 235000020183 skimmed milk Nutrition 0.000 claims abstract description 12
- 230000035764 nutrition Effects 0.000 claims abstract description 11
- 241001465754 Metazoa Species 0.000 claims abstract description 5
- 230000008569 process Effects 0.000 claims abstract description 5
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 4
- 239000004615 ingredient Substances 0.000 claims description 27
- 230000001954 sterilising effect Effects 0.000 claims description 27
- 238000002156 mixing Methods 0.000 claims description 20
- 238000004659 sterilization and disinfection Methods 0.000 claims description 18
- 238000001694 spray drying Methods 0.000 claims description 17
- 241001134770 Bifidobacterium animalis Species 0.000 claims description 13
- 229940118852 bifidobacterium animalis Drugs 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 10
- 239000003921 oil Substances 0.000 claims description 10
- 235000019198 oils Nutrition 0.000 claims description 10
- 238000001704 evaporation Methods 0.000 claims description 9
- 230000008020 evaporation Effects 0.000 claims description 9
- 235000019534 high fructose corn syrup Nutrition 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 8
- 239000003240 coconut oil Substances 0.000 claims description 7
- 235000019864 coconut oil Nutrition 0.000 claims description 7
- 239000002285 corn oil Substances 0.000 claims description 7
- 235000005687 corn oil Nutrition 0.000 claims description 7
- 235000020238 sunflower seed Nutrition 0.000 claims description 7
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 6
- 229960004172 pyridoxine hydrochloride Drugs 0.000 claims description 6
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims description 6
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims description 6
- 229960000344 thiamine hydrochloride Drugs 0.000 claims description 6
- 235000019190 thiamine hydrochloride Nutrition 0.000 claims description 6
- 239000011747 thiamine hydrochloride Substances 0.000 claims description 6
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 5
- ZAKOWWREFLAJOT-UHFFFAOYSA-N DL-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 5
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 claims description 5
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 claims description 5
- 239000002211 L-ascorbic acid Substances 0.000 claims description 5
- 235000000069 L-ascorbic acid Nutrition 0.000 claims description 5
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 5
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 5
- 229960005070 ascorbic acid Drugs 0.000 claims description 5
- 229960003563 calcium carbonate Drugs 0.000 claims description 5
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 claims description 5
- 235000000639 cyanocobalamin Nutrition 0.000 claims description 5
- 239000011666 cyanocobalamin Substances 0.000 claims description 5
- 229960000304 folic acid Drugs 0.000 claims description 5
- 235000019152 folic acid Nutrition 0.000 claims description 5
- 239000011724 folic acid Substances 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 5
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 5
- 235000005282 vitamin D3 Nutrition 0.000 claims description 5
- 239000011647 vitamin D3 Substances 0.000 claims description 5
- 229940021056 vitamin d3 Drugs 0.000 claims description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 4
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 4
- 229940117373 dl-alpha tocopheryl acetate Drugs 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 4
- 238000007599 discharging Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000003623 enhancer Substances 0.000 claims description 3
- 239000011552 falling film Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000000828 canola oil Substances 0.000 claims description 2
- 235000019519 canola oil Nutrition 0.000 claims description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 2
- 235000019175 phylloquinone Nutrition 0.000 claims description 2
- 239000011772 phylloquinone Substances 0.000 claims description 2
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 claims description 2
- 229960001898 phytomenadione Drugs 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 235000021433 fructose syrup Nutrition 0.000 abstract description 3
- 235000013365 dairy product Nutrition 0.000 abstract 1
- 238000011031 large-scale manufacturing process Methods 0.000 abstract 1
- 235000010755 mineral Nutrition 0.000 description 14
- 238000011161 development Methods 0.000 description 13
- 230000018109 developmental process Effects 0.000 description 13
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 8
- 206010057249 Phagocytosis Diseases 0.000 description 7
- 210000002540 macrophage Anatomy 0.000 description 7
- 230000008782 phagocytosis Effects 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 5
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 235000019484 Rapeseed oil Nutrition 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 229930182470 glycoside Natural products 0.000 description 5
- 150000002338 glycosides Chemical class 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 5
- 229910000368 zinc sulfate Inorganic materials 0.000 description 5
- 229960001763 zinc sulfate Drugs 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 240000006509 Gynostemma pentaphyllum Species 0.000 description 4
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000011790 ferrous sulphate Substances 0.000 description 4
- 235000003891 ferrous sulphate Nutrition 0.000 description 4
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 4
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 4
- 235000012711 vitamin K3 Nutrition 0.000 description 4
- 239000011652 vitamin K3 Substances 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- 229940041603 vitamin k 3 Drugs 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 229910000365 copper sulfate Inorganic materials 0.000 description 3
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 3
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 239000011781 sodium selenite Substances 0.000 description 3
- 229960001471 sodium selenite Drugs 0.000 description 3
- 235000015921 sodium selenite Nutrition 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 229960000342 retinol acetate Drugs 0.000 description 2
- 235000019173 retinyl acetate Nutrition 0.000 description 2
- 239000011770 retinyl acetate Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037208 balanced nutrition Effects 0.000 description 1
- 235000019046 balanced nutrition Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- JWEKFMCYIRVOQZ-UHFFFAOYSA-N cyanamide;sodium Chemical compound [Na].NC#N JWEKFMCYIRVOQZ-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000004392 development of vision Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 208000018997 giddiness Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000003563 glycoside group Chemical group 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 229930187479 gypenoside Natural products 0.000 description 1
- ZRBFCAALKKNCJG-UHFFFAOYSA-N gypenoside-XVII Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O ZRBFCAALKKNCJG-UHFFFAOYSA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 235000010692 trans-unsaturated fatty acids Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/16—Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1522—Inorganic additives, e.g. minerals, trace elements; Chlorination or fluoridation of milk; Organic salts or complexes of metals other than natrium or kalium; Calcium enrichment of milk
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1528—Fatty acids; Mono- or diglycerides; Petroleum jelly; Paraffine; Phospholipids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/156—Flavoured milk preparations ; Addition of fruits, vegetables, sugars, sugar alcohols or sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/158—Milk preparations; Milk powder or milk powder preparations containing additives containing vitamins or antibiotics
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a children formula milk powder for improving immunity, and belongs to the technical field of dairy products. The formula milk powder contains 180-375 parts of skimmed milk powder, 95-150 parts of concentrated whey protein powder, 90-110 parts of vegetable oil, 65 parts of 1, 3-dioleate-2-palmitic acid triglyceride, 130-235 parts of high fructose syrup, 300 parts of lactose 220-containing powder, 2 parts of compound vitamin, 1 part of compound mineral, 7 parts of calcium carbonate, 0.58 part of choline chloride, 0.4 part of taurine, 6.58 parts of fructo-oligosaccharide, 2.4 parts of docosahexaenoic acid powder, 2 parts of bovine colostrum powder, 1.1 part of lactoferrin powder, 0.2 part of N-acetylneuraminic acid and 0.3 part of freeze-dried animal bifidobacterium Bb-12 powder. The children formula milk powder disclosed by the invention is balanced in nutrition and can effectively improve the immunity. The method for preparing the children milk powder has simple process flow and easy operation, and is suitable for large-scale production.
Description
Technical Field
The invention relates to the field of children formula milk powder, in particular to children formula milk powder capable of improving organism immunity and a preparation method thereof.
Background
The children formula milk powder is a very important nutritional supplement food in the dietary structure of children, and can supplement a large amount of high-quality protein, vitamins and minerals for children. The invention is suitable for the minor (1-10 years old children) with the age of 1 year old and less than 10 years old, and is divided into two stages of preschool children with the age of 1-5 years old and school children with the age of 6-10 years old.
As is known, the age of 1-5 years is a critical period of growth of children, the digestive system is not fully developed and mature, the immune function is poor, and 400 ml of proper formula milk powder needs to be supplemented every day to obtain sufficient nutrition. The children aged 6 enter the education stage of school, the growth and development are rapid, the requirement for energy and nutrients is relatively higher than that of adults, 500ml of milk product is still required every day, and sufficient nutrition can promote the normal development of intelligence and physique of the children and improve the immunity.
Most of the milk powder sold in the market is infant formula milk powder and middle-aged and elderly milk powder, the variety of the infant formula milk powder is few, or the purposes of brain development and skeleton development of children are mainly taken, and the current situations of protecting intestinal tracts, promoting absorption and improving the immunity of organisms are ignored. The development of the formula milk powder which has reasonable nutrition structure and is mainly used for promoting the comprehensive growth of vision, intelligence and the like of children by improving the immunity is necessary, and the formula milk powder belongs to one of the current important research and development subjects.
Disclosure of Invention
The invention relates to a nutritional supplement food which is specially designed and produced aiming at the growth and development characteristics of children and teenagers, and is added with a plurality of groups of nutritional components, aiming at providing a children formula milk powder which can improve the immunity of the organism, has balanced nutrition, can protect the intestinal tract and is easy to absorb, and can promote the development of vision and intelligence.
Specifically, the technical scheme of the invention is as follows:
a children formula milk powder comprises the following components in kg by weight per 1000kg of finished products: the formula comprises 180kg of skimmed milk powder, 95kg to 150kg of concentrated whey protein powder, 90kg to 110kg of vegetable oil, 65kg of 1, 3-dioleate-2-palmitic acid triglyceride, 130kg of high fructose syrup, 300kg of lactose 220-containing powder, 2kg of compound vitamin, 1kg of compound mineral substance, 7kg of calcium carbonate, 0.58kg of choline chloride, 0.4kg of taurine, 6.58kg of fructo-oligosaccharide, 2.4kg of docosahexaenoic acid powder, 2kg of bovine colostrum powder, 1.1kg of lactoferrin powder, 0.2kg of N-acetylneuraminic acid and 0.3kg of freeze-dried powder of bifidobacterium animalis Bb-12.
Preferably, in the technical scheme, each 1000kg of the cow colostrum powder contains 95-150kg of concentrated whey protein powder, 1.1kg of lactoferrin powder containing lactoferrin and 2kg of bovine colostrum powder.
Preferably, in the technical scheme, 0.3kg of bifidobacterium animalis Bb-12 freeze-dried powder and 6.58kg of fructo-oligosaccharide are added into every 1000kg of the bifidobacterium animalis Bb-12 freeze-dried powder.
In the preferable technical scheme, in kg, in every 1000kg, the docosahexaenoic acid powder contains 2.4kg, wherein the content of the docosahexaenoic acid oil accounts for 11 percent, the content of the N-acetylneuraminic acid is 0.2kg, and the content of the taurine is 0.4 kg.
Preferably, in the technical scheme, in kg, the 1, 3-dioleoyl-2-palmitic acid triglyceride contains 65kg per 1000kg, and the effective content is 40%;
the vegetable oil comprises, by kg, per 1000kg, 27-55kg of sunflower seed oil, 18-33kg of low erucic acid rapeseed oil, 9-27.5kg of coconut oil and 9-27.5kg of corn oil.
The compound vitamin contains, by g, per 1000kg of retinyl acetate 5.616-7.598 g RE, cholecalciferol 0.074g-0.1g, dl- α -tocopherol acetate 18-24g, phytomenadione 0.638-0.862g, thiamine hydrochloride 5.95-8.05g, pyridoxine hydrochloride 4.676-6.326g, cyanocobalamine 0.004-0.006g, nicotinamide 32.3-43.7g, folic acid 1.87-2.53g, L-ascorbic acid 850-.
The compound mineral substance comprises, by g, every 1000kg contains 282g of ferrous sulfate 209-.
The technical scheme of the invention has the following beneficial effects:
(1) the invention adds the combination for improving the immunity of the organism: concentrated whey protein powder, lactoferrin powder and bovine colostrum powder. The concentrated whey protein used in the invention contains 1% of lactoferrin, the lactoferrin is a natural glycoprotein with an immunologic function, and has the functions of promoting iron absorption, regulating macrophage activity, stimulating lymphocyte synthesis to improve immunity, inhibiting bacteria, resisting viruses, blocking oxygen free radicals, avoiding stimulating intestines and stomach, promoting bifidobacterium growth and the like; the colostrum refers to milk secreted by cow within 7d after calving. It features rich nutrients and active substances, and its chemical composition is similar to that of human milk in all stored milk, so promoting growth and development and raising immunity.
(2) The invention adds the combination for protecting the intestinal tract: probiotic bacteria + fructo-oligosaccharides. The bifidobacterium animalis Bb-12 and fructo-oligosaccharide have synergistic effect, and can effectively increase the content of beneficial bacteria in intestinal tracts, regulate the intestinal flora, inhibit the growth of harmful bacteria, protect intestinal mucosa, improve the symptoms of constipation or diarrhea and the like, and promote the absorption of nutrient substances.
(3) The invention adds the combination for promoting the development of the nervous system and the vision: n-acetylneuraminic acid + docosahexaenoic acid + taurine. The N-acetylneuraminic acid can effectively promote the development and functional repair of nerve cells, epithelial cells and immune cells, has the effects of improving immunity and promoting intelligence development, docosahexaenoic acid is an important component of cerebral cortex and retina, taurine has the effect of improving the light injury of the retina, and the composition can effectively protect and promote the development of a nervous system and vision.
(4) The invention adds fat optimization combination: vegetable oil + OPO structural lipid. Wherein the vegetable oil is a mixture of sunflower seed oil, canola oil, coconut oil and corn oil, contains n-3, n-6 polyunsaturated fatty acids, and does not contain hydrogenated oils and trans-fatty acids; the OPO structure fat is a mother emulsified fat structure, can prevent the formation of calcium soap, and can reduce the risk of constipation.
(5) The invention adds a plurality of vitamin mineral compositions: provides a plurality of vitamin minerals required by the growth of children and teenagers, effectively avoids the growth retardation caused by lack of nutrition, and the like, and balances the nutrition and helps the growth.
In conclusion, the children formula milk powder is specially developed according to the growth and development characteristics of children and teenagers and the dietary nutrition recommendation of WHO and Chinese nutritional society, is beneficial to the growth and development of children, and has good taste and easy absorption. The formula milk powder can effectively improve the body immunity of children and teenagers.
The invention also discloses a preparation method of the children milk powder, which specifically comprises the following steps:
the method comprises the following steps: the first mixing specifically comprises: uniformly mixing skim milk powder, concentrated whey protein powder, vegetable oil, 1, 3-dioleate-2-palmitic acid triglyceride, lactose, high fructose corn syrup and water in a predetermined weight ratio to obtain a first ingredient;
step two: homogenizing, specifically: homogenizing the first ingredient obtained in the step one in a high-pressure homogenizer to obtain a second ingredient, wherein the homogenizing pressure is 15-20 Mpa;
step three: high-temperature sterilization, specifically comprising: sterilizing the second ingredient obtained in the step two in a plate heat exchanger, wherein the sterilization temperature is 119-125 ℃, and the sterilization time is 4-6S;
step four: and (3) mixing for the second time, specifically: adding the food nutrition enhancer added with the compound vitamins, the compound mineral substances, calcium carbonate, choline chloride and taurine into the premix, and mixing with the second ingredient to obtain a third ingredient;
step five: sterilizing and concentrating, specifically: and (3) sterilizing and concentrating the third ingredient in a three-effect multi-flow falling film evaporator, wherein the sterilization temperature is 100-106 ℃, the sterilization time is 24s, and the one-effect evaporation temperature is as follows: 70-80 ℃, double-effect evaporation temperature: 65-70 ℃, triple effect evaporation temperature: concentrating the obtained milk to a dry matter content of 40-50% at 60-70 ℃ to obtain a fourth ingredient;
step six: spray drying, specifically: and (3) carrying out spray drying on the fourth ingredient by a spray drying tower, wherein the spray equipment is an upper-exhaust vertical pressure spray drying tower, and the process conditions are as follows: the air inlet temperature of spray drying is 185-195 ℃, the air outlet temperature is 80-89 ℃, the negative pressure in the tower is 0-10mm water column, and the pressure of the high-pressure pump is 10-20 Mpa; and performing secondary drying on the powder by a fluidized bed to obtain powder, wherein the powder discharging temperature is less than or equal to 25 ℃, and the water content is less than or equal to 5.0 percent to obtain base powder;
step seven: premixing, specifically, premixing fructo-oligosaccharide, docosahexaenoic acid powder, lactoferrin powder, bovine colostrum powder, N-acetylneuraminic acid and bifidobacterium animalis Bb-12 freeze-dried powder according to the addition amount;
step eight: mixing, namely mixing the base powder and the premix obtained in the step seven according to a formula ratio to obtain finished powder;
step nine: and packaging, detecting and warehousing.
Compared with the prior art, the formula milk powder for children provided by the invention has the advantages that multiple groups of nutrient components are added, the body immunity of children, especially children aged 1-10 years is improved, the nutrition balance can be kept, the intestinal tract is protected, the absorption is easy, and the vision and intelligence development can be promoted.
Detailed Description
The invention discloses a children formula milk powder capable of improving body immunity and a preparation method thereof, and a person skilled in the art can appropriately change process parameters by referring to the contents in the text. It is expressly intended that all such similar substitutes and modifications which would be obvious to one skilled in the art are deemed to be included in the invention. While the methods and applications of this invention have been described in terms of preferred embodiments, it will be apparent to those of ordinary skill in the art that variations and modifications in the methods and applications described herein, as well as other suitable variations and combinations, may be made to implement and use the techniques of this invention without departing from the spirit and scope of the invention.
Example 1: a formula milk powder for children capable of improving organism immunity comprises the following components by weight:
300kg of skimmed milk powder, 100kg of concentrated whey protein powder, 65kg of 1, 3-dioleate-2-palmitic acid triglyceride, 95kg of vegetable oil, 140kg of high fructose corn syrup, 295kg of lactose, 2kg of compound vitamin, 1kg of compound mineral substance, 7kg of calcium carbonate, 0.58kg of choline chloride, 0.4kg of taurine, 6.58kg of fructo-oligosaccharide, 2.4kg of docosahexaenoic acid powder, 2kg of bovine colostrum powder, 1.1kg of lactoferrin powder, 0.2kg of N-acetylneuraminic acid and 0.3kg of bifidobacterium animalis Bb-12 freeze-dried powder.
The vegetable oil is a mixture of 38kg of sunflower seed oil, 23.75kg of low erucic acid rapeseed oil, 16.625kg of coconut oil and 16.625kg of corn oil.
The compound vitamin comprises 6.607g RE acetate, 0.087g cholecalciferol, 21g dl- α -tocopheryl acetate, 0.75g plant menadione, 7.0g thiamine hydrochloride, 5.501g pyridoxine hydrochloride, 0.005g cyanocobalamine, 38g nicotinamide, 2.2g folic acid and 1000g L-ascorbic acid.
The compound mineral substance is 245.5g of ferrous sulfate, 174.5g of zinc sulfate, 0.014g of copper sulfate and 0.00025g of sodium selenite.
A children formula milk powder capable of improving organism immunity is prepared by the following steps:
the method comprises the following steps: the first mixing specifically comprises: uniformly mixing skim milk powder, concentrated whey protein powder, vegetable oil, 1, 3-dioleate-2-palmitic acid triglyceride, lactose, high fructose corn syrup and water in a predetermined weight ratio to obtain a first ingredient;
step two: homogenizing, specifically: homogenizing the first ingredient obtained in the step one in a high-pressure homogenizer to obtain a second ingredient, wherein the homogenizing pressure is 15-20 Mpa;
step three: high-temperature sterilization, specifically comprising: sterilizing the second ingredient obtained in the step two in a plate heat exchanger, wherein the sterilization temperature is 119-125 ℃, and the sterilization time is 4-6S;
step four: and (3) mixing for the second time, specifically: adding the food nutrition enhancer added with the compound vitamins, the compound mineral substances, calcium carbonate, choline chloride and taurine into the premix, and mixing with the second ingredient to obtain a third ingredient;
step five: sterilizing and concentrating, specifically: and (3) sterilizing and concentrating the third ingredient in a three-effect multi-flow falling film evaporator, wherein the sterilization temperature is 100-106 ℃, the sterilization time is 24s, and the one-effect evaporation temperature is as follows: 70-80 ℃, double-effect evaporation temperature: 65-70 ℃, triple effect evaporation temperature: concentrating the obtained milk to a dry matter content of 40-50% at 60-70 ℃ to obtain a fourth ingredient;
step six: spray drying, specifically: and (3) carrying out spray drying on the fourth ingredient by a spray drying tower, wherein the spray equipment is an upper-exhaust vertical pressure spray drying tower, and the process conditions are as follows: the air inlet temperature of spray drying is 185-195 ℃, the air outlet temperature is 80-89 ℃, the negative pressure in the tower is 0-10mm water column, and the pressure of the high-pressure pump is 10-20 Mpa; and performing secondary drying on the powder by a fluidized bed to obtain powder, wherein the powder discharging temperature is less than or equal to 25 ℃, and the water content is less than or equal to 5.0 percent to obtain base powder;
step seven: premixing, specifically, premixing fructo-oligosaccharide, docosahexaenoic acid powder, cow milk primary powder, lactoferrin powder, N-acetylneuraminic acid and bifidobacterium animalis Bb-12 freeze-dried powder according to the addition amount;
step eight: mixing, namely mixing the base powder and the premix obtained in the step seven according to a formula ratio to obtain finished powder;
step nine: and packaging, detecting and warehousing.
Example 2: a formula milk powder for children capable of improving organism immunity comprises the following components by weight:
180kg of skimmed milk powder, 150kg of concentrated whey protein powder, 65kg of 1, 3-dioleate-2-palmitic acid triglyceride, 90kg of vegetable oil, 235kg of high fructose corn syrup, 300kg of lactose, 2kg of compound vitamin, 1kg of compound mineral matter, 7kg of calcium carbonate, 0.58kg of choline chloride, 0.4kg of taurine, 6.58kg of fructo-oligosaccharide, 2.4kg of docosahexaenoic acid powder, 2kg of bovine colostrum powder, 1.1kg of lactoferrin powder, 0.2kg of N-acetylneuraminic acid and 0.3kg of bifidobacterium animalis Bb-12 freeze-dried powder.
The vegetable oil is a mixture of 36kg of sunflower seed oil, 22.5kg of low erucic acid rapeseed oil, 15.75kg of coconut oil and 15.75kg of corn oil.
The compound vitamin contains 5.616g RE acetate, 0.074gg cholecalciferol, 184g dl- α -tocopheryl acetate, 0.6382g plant menadione, 5.955g thiamine hydrochloride, 4.676g pyridoxine hydrochloride, 0.004g cyanocobalamine, 32.3g nicotinamide, 1.87g folic acid and 850g L-ascorbic acid.
The compound mineral comprises 209g of ferrous sulfate, 149g of zinc sulfate, 0.012g of copper sulfate and 0.0002g of sodium selenite.
The specific preparation method is the same as that of example 1.
Example 3: a formula milk powder for children capable of improving organism immunity comprises the following components by weight:
375kg of skimmed milk powder, 95kg of concentrated whey protein powder, 65kg of 1, 3-dioleate-2-palmitic acid triglyceride, 110kg of vegetable oil, 130kg of high fructose corn syrup, 220kg of lactose, 2kg of compound vitamin, 1kg of compound mineral substance, 7kg of calcium carbonate, 0.58kg of choline chloride, 0.4kg of taurine, 6.58kg of fructo-oligosaccharide, 2.4kg of docosahexaenoic acid powder, 2kg of bovine colostrum powder, 1.1kg of lactoferrin powder, 0.2kg of N-acetylneuraminic acid and 0.3kg of bifidobacterium animalis Bb-12 freeze-dried powder.
The vegetable oil is a mixture of 44kg of sunflower seed oil, 27.5kg of low erucic acid rapeseed oil, 19.25kg of coconut oil and 19.25kg of corn oil.
The compound vitamin contains 7.598g RE acetate, 0.1g cholecalciferol, 24g dl- α -tocopheryl acetate, 0.862g plant menadione, 8.05g thiamine hydrochloride, 6.326g pyridoxine hydrochloride, 0.006g cyanocobalamine, 43.7g nicotinamide, 2.53g folic acid and 1150g L-ascorbic acid.
The compound mineral comprises 282g of ferrous sulfate, 200g of zinc sulfate, 0.016g of copper sulfate and 0.0003g of sodium selenite.
The specific preparation method is the same as that of example 1.
Verification example 1:
in order to further verify the milk powder of the formula of the invention, animal experiments were carried out on the products related to the invention, and the following animal experiment conditions were as follows:
1. material
1.1 license number: SYXK (lu) 20180008, production unit: lunan pharmaceutical group, Kunming mouse, both male and female, weighing 18-22 g.
Gypenoside tablets and formula milk powder sold in the market. The herba Gynostemmatis total glycosides have effects of reducing blood lipid, improving myocardial ischemia and anoxia, protecting cerebral ischemia, and resisting oxidation. Nourishing heart and invigorating spleen, invigorating qi and regulating blood, eliminating phlegm and removing blood stasis, and is suitable for hyperlipidemia with symptoms of heart and spleen qi deficiency, phlegm stagnation and blood stasis, such as palpitation, short breath, chest distress, limb numbness, giddiness, headache, amnesia, tinnitus, spontaneous perspiration, asthenia, or abdominal distention; the formula milk powder sold in the market is mainly used for improving the immunity and balancing the nutrient substances.
The formula milk powder of the embodiment 1 mainly comprises 300kg of skimmed milk powder, 100kg of concentrated whey protein powder, 65kg of 1, 3-dioleate-2-palmitic acid triglyceride, 95kg of vegetable oil, 140kg of fructose syrup, 295kg of lactose, 2kg of compound vitamin, 1kg of compound mineral, 7kg of calcium carbonate, 0.58kg of choline chloride, 0.4kg of taurine, 6.58kg of fructo-oligosaccharide, 2.4kg of docosahexaenoic acid powder, 2kg of bovine colostrum powder, 1.1kg of lactoferrin powder, 0.2kg of N-acetylneuraminic acid, 0.3kg of animal bifidobacterium Bb-12 freeze-dried powder, 38kg of sunflower seed oil, 23.75kg of low erucic acid rapeseed oil, 16.625kg of coconut oil and 16.625kg of corn oil, 6.607g of compound vitamin mixture of retinyl acetate, RE, 0.087g of calcium cholate, α -tocopheryl acetate, 21g of plant menadione, 7.0.0 g of thiamine hydrochloride, 5.501g of pyridoxine hydrochloride, 0.2 g of sodium cyanamide, 2g of zinc sulfate, 1000.5 g of vitamin L-2 g of vitamin and 1000.5 g of zinc sulfate.
The preparation method comprises the following steps: the preparation of example 1 of the present invention.
2. Method of producing a composite material
2.1 Effect on phagocytic function of macrophages in mouse peritoneal cavity
60 mice are divided into 6 groups at random, wherein 5 groups are respectively filled with high, medium and low dose contents of the formula milk powder,
1 time of administration of herba Gynostemmatis total glycoside tablet suspension and commercially available formula milk powder for 10 days; the control group was drenched with equal volume of distilled water.
The experimental mice are killed by intraperitoneal injection of 5% of chicken blood erythrocytes, 0.2ml of each mouse and cervical dislocation after 2 hours, 0.5ml of normal saline is immediately injected into the abdominal cavity, the abdominal cavity is gently kneaded for 2 minutes, then the abdominal skin is cut, a small opening is formed in a muscle layer, the abdominal cavity liquid is taken out and pushed on a clean glass slide, the incubation is carried out for 30 minutes at 37 ℃, microscopic examination is carried out after staining, and direct observation and statistics are carried out under a microscope, so that 2000 macrophages are contained in each mouse.
Phagocytosis rate and phagocytosis index were calculated: the phagocytosis rate F (number of macrophages engulfmg chicken blood erythrocytes/2000) X100%, and the phagocytosis index F (total number of chicken blood erythrocytes engulfed/number of macrophages engulfmg chicken red blood cells).
3. Results
After 10 consecutive days, the above experimental data were statistically processed, specifically by SPSS17.0 software, with the results shown in table 1:
as can be seen from table 1: compared with the control group, the formula milk powder product and the gynostemma total glycoside group of the invention of the embodiment 1 with high, medium and low doses can obviously improve the phagocytosis rate and the phagocytosis index of abdominal macrophages of normal mice, which indicates that the phagocytosis rate of abdominal macrophages of experimental mice on chicken red blood cells can be enhanced, and the cellular immune function of the mice can be improved. Compared with the commercial formula milk powder, the high, medium and low dosages of the gynostemma total glycoside tablet in the embodiment 1 have significant difference (P <0.05 or P < 0.01), and compared with the high and medium dosages of the gynostemma total glycoside tablet in the embodiment 1, the high, medium and low dosages of the gynostemma total glycoside tablet have significant difference (P <0.05 or P < 0.01). This also demonstrates the experimental benefit of the present invention over the prior art.
Verification example 2:
the milk powder disclosed by the invention has influence on the resistance of children, 20 children aged 2.5 years after weaning are selected as group subjects, and the conditions such as height, age and the like of the children are not obviously different from half male to half female.
The method comprises the following steps: 20 children were randomly divided into two groups, each group being male and female halves. The experimental group was fed with the milk powder of example 1 of the present invention, the observation group was fed with the commercially available milk powder, supplemented with the normal diet, and observed after 3 months of feeding, and all children were tested for height, weight, CD3+ content, and CD4+/CD8 +.
As a result: the results obtained for the data were all statistically processed using SPSS 17.0. Statistics are carried out by adopting +/-as follows:
as can be seen from table 2, the height of girls was significantly different between the experimental group and the observers, while there was no significant difference between the experimental group and the observers with respect to the height of boys and the weight of boys and girls.
As can be seen from Table 3, the content of CD3+ and the ratio of CD4+/CD8+ were significantly different in the observation group and the experimental group (P < 0.05). Within a certain range, the higher the content of CD3+ (normal range 955-; the ratio of CD4+/CD8+ (normal range is 1.00-2.87) is mainly used for judging clinical diagnosis sensitive indexes of human immune dysfunction.
Claims (10)
1. The children formula milk powder is characterized by mainly comprising the following components: skimmed milk powder, concentrated whey protein powder, vegetable oil, 1, 3-dioleic acid-2-palmitic acid triglyceride, lactose, high fructose corn syrup, compound vitamins, compound minerals, calcium carbonate, choline chloride, taurine, fructo-oligosaccharide, docosahexaenoic acid powder, bovine colostrum powder, lactoferrin powder, N-acetylneuraminic acid and bifidobacterium animalis Bb-12 freeze-dried powder.
2. The children's formula according to claim 1, wherein: the formula milk powder for children comprises, per 1000kg of finished milk powder, 180-375kg of skimmed milk powder, 95-150kg of concentrated whey protein powder, 90-110kg of vegetable oil, 65kg of 1, 3-dioleate-2-palmitic triglyceride, 130-235kg of high fructose corn syrup, 300kg of lactose 220-one, 2kg of compound vitamin, 1kg of compound mineral, 7kg of calcium carbonate, 0.58kg of choline chloride, 0.4kg of taurine, 6.58kg of fructo-oligosaccharide, 2.4kg of docosahexaenoic acid powder, 2kg of bovine colostrum powder, 1.1kg of lactoferrin powder, 0.2kg of N-acetylneuraminic acid and 0.3kg of bifidobacterium animalis Bb-12 freeze-dried powder.
3. The children formula milk powder as claimed in claim 2, wherein the vegetable oil is a mixture of 27-55kg of sunflower seed oil, 18-33kg of canola oil, 9-27.5kg of coconut oil and 9-27.5kg of corn oil, the compound vitamins are 5.616-7.598 g of RE acetate, 0.074g-0.1g of cholecalciferol, 18-24g of dl- α -tocopheryl acetate, 0.638-0.862g of phytomenadione, 5.95-8.05g of thiamine hydrochloride, 4.676-6.326g of pyridoxine hydrochloride, 0.004-0.006g of cyanocobalamine, 32.3-43.7g of nicotinamide, 1.87-2.53g of folic acid and 1150g of L-ascorbic acid 850-.
4. The children's formula according to claim 2, wherein: in 1000kg of milk powder, the milk powder contains 95-150kg of concentrated whey protein powder, 1.1kg of lactoferrin powder and 2kg of bovine colostrum powder in kg; every 1000kg of milk powder contains animal Bifidobacterium Bb-1210 in g6CFU/g; comprises 6.58kg of fructo-oligosaccharide in kg; in kg, the docosahexaenoic acid powder contains 2.4kg, wherein the content of docosahexaenoic acid oil accounts for 11%; the content of N-acetylneuraminic acid is 0.2kg; the taurine content is 0.4 kg; the content of 1, 3-dioleoyl-2-palmitic acid triglyceride was 65kg in kg, wherein the effective content was 40%.
5. Children's formula according to claim 4, characterized in that: the concentrated whey protein powder used contained 1% lactoferrin.
6. A method of preparing a children's formula according to any of claims 1 to 5, comprising the steps of:
a) mixing skimmed milk powder, concentrated whey protein powder, vegetable oil, 1, 3-dioleate-2-palmitic acid triglyceride, lactose, high fructose corn syrup, compound vitamins, compound minerals, calcium carbonate, choline chloride and taurine with water, and homogenizing to obtain a mixed solution;
b) sterilizing, concentrating and spray-drying the mixed solution obtained in the step a) to obtain powder;
c) adding docosahexaenoic acid powder, fructo-oligosaccharide, bovine colostrum powder, lactoferrin powder, N-acetylneuraminic acid and bifidobacterium animalis Bb-12 freeze-dried powder into the powder obtained in the step b), screening the powder, inspecting the powder by metal detection, and packaging the qualified powder to obtain the feed.
7. The method for preparing a children's formula according to claim 6, wherein the mixing temperature is 50-65 ℃ and the homogenizing pressure is 15-20Mpa in step a).
8. The method for preparing a milk formula for children as claimed in claim 6, wherein in step b), the sterilization temperature is 100 ℃ and the sterilization time is 24S; the air inlet temperature of spray drying is 185-195 ℃, and the air outlet temperature is 80-89 ℃.
9. Method for preparing a children's formula according to claim 6, characterized in that it comprises the following steps:
the method comprises the following steps: mixing for the first time: uniformly mixing skim milk powder, concentrated whey protein powder, vegetable oil, 1, 3-dioleate-2-palmitic acid triglyceride, lactose, high fructose corn syrup and water in a predetermined weight ratio to obtain a first ingredient;
step two: homogenizing, specifically: homogenizing the first ingredient obtained in the step one in a high-pressure homogenizer to obtain a second ingredient, wherein the homogenizing pressure is 15-20 Mpa;
step three: high-temperature sterilization: sterilizing the second ingredient obtained in the step two in a plate heat exchanger, wherein the sterilization temperature is 119-125 ℃, and the sterilization time is 4-6S;
step four: and (3) mixing for the second time: adding the food nutrition enhancer added with the compound vitamins, the compound mineral substances, calcium carbonate, choline chloride and taurine into the premix, and mixing with the second ingredient to obtain a third ingredient;
step five: sterilization and concentration: and (3) sterilizing and concentrating the third ingredient in a three-effect multi-flow falling film evaporator, wherein the sterilization temperature is 100-106 ℃, the sterilization time is 24s, and the one-effect evaporation temperature is as follows: 70-80 ℃, double-effect evaporation temperature: 65-70 ℃, triple effect evaporation temperature: concentrating the obtained milk to a dry matter content of 40-50% at 60-70 ℃ to obtain a fourth ingredient;
step six: spray drying: and (3) carrying out spray drying on the fourth ingredient by a spray drying tower, wherein the spray equipment is an upper-exhaust vertical pressure spray drying tower, and the process conditions are as follows: the air inlet temperature of spray drying is 185-195 ℃, the air outlet temperature is 80-89 ℃, the negative pressure in the tower is 0-10mm water column, and the pressure of the high-pressure pump is 10-20 Mpa; and performing secondary drying on the powder by a fluidized bed to obtain powder, wherein the powder discharging temperature is less than or equal to 25 ℃, and the water content is less than or equal to 5.0 percent to obtain base powder;
step seven: premixing: premixing fructo-oligosaccharide, docosahexaenoic acid powder, milk primary powder, lactoferrin powder, N-acetylneuraminic acid and bifidobacterium animalis Bb-12 freeze-dried powder according to the addition amount;
step eight: mixing, namely mixing the base powder and the premix obtained in the step seven according to a formula ratio to obtain finished powder;
step nine: and packaging, detecting and warehousing.
10. Use of a children's formula according to any of claims 1-5 for improving the immunity of children of 1-10 years of age.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010122634.XA CN111011522A (en) | 2020-02-27 | 2020-02-27 | Children formula milk powder capable of improving immunity and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010122634.XA CN111011522A (en) | 2020-02-27 | 2020-02-27 | Children formula milk powder capable of improving immunity and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111011522A true CN111011522A (en) | 2020-04-17 |
Family
ID=70199477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010122634.XA Pending CN111011522A (en) | 2020-02-27 | 2020-02-27 | Children formula milk powder capable of improving immunity and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111011522A (en) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111758782A (en) * | 2020-07-09 | 2020-10-13 | 安徽贝尔宝母婴用品有限公司 | Milk powder beneficial to improving immunity and preparation method thereof |
| CN111990461A (en) * | 2020-08-18 | 2020-11-27 | 北安宜品努卡乳业有限公司 | Mixed milk powder for enhancing immunity and preparation method thereof |
| CN112471260A (en) * | 2020-11-25 | 2021-03-12 | 中宁县黄河乳制品有限公司 | Organic formula milk powder for improving human immunity and preparation method thereof |
| CN112471259A (en) * | 2020-11-25 | 2021-03-12 | 中宁县黄河乳制品有限公司 | Formula milk powder for promoting growth of height of children and preparation method thereof |
| CN112715946A (en) * | 2021-01-08 | 2021-04-30 | 美蓓(无锡)营养科技有限公司 | Sialic acid children nutrition bag |
| CN112753777A (en) * | 2021-01-27 | 2021-05-07 | 培臻生物科技(上海)有限公司 | Milk powder for improving immunity and preparation method thereof |
| CN113678898A (en) * | 2020-05-19 | 2021-11-23 | 培臻生物科技(上海)有限公司 | Milk powder beneficial to development and growth of children and preparation method thereof |
| CN113796424A (en) * | 2021-07-05 | 2021-12-17 | 百跃羊乳(南宁)有限公司 | Anti-infection children fruit and vegetable flavor formula sheep milk powder and preparation method thereof |
| CN115191488A (en) * | 2022-05-13 | 2022-10-18 | 湖南袁氏农牧科技发展有限公司 | A kind of formula milk powder for improving immunity of children and preparation method thereof |
| CN116548608A (en) * | 2023-05-06 | 2023-08-08 | 北安宜品努卡乳业有限公司 | Full-nutrition formula powder for children and preparation method and application thereof |
| CN117281177A (en) * | 2023-07-28 | 2023-12-26 | 至同(杭州)健康科技有限公司 | Nutrient for stimulating intrinsic resistance of people over 3 years old and preparation method thereof |
| CN118415241A (en) * | 2024-05-23 | 2024-08-02 | 馨辰生物(广东)有限公司 | Bovine colostrum body-enhancing composition, solid beverage and oral liquid beverage |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040202765A1 (en) * | 2003-04-14 | 2004-10-14 | Mcmahon Robert J. | Compositions and methods of formulation for enteral formulas containing sialic acid |
| CN105746728A (en) * | 2016-03-14 | 2016-07-13 | 上海晨冠乳业有限公司 | Infant formula milk powder simulating breast milk and preparation method of infant formula milk powder |
| CN106578092A (en) * | 2016-12-21 | 2017-04-26 | 海普诺凯营养品有限公司 | Children milk powder and making method thereof |
| CN109287759A (en) * | 2018-11-21 | 2019-02-01 | 上海育博营养食品有限公司 | A kind of formula milk and production method helping child height development |
| CN110074190A (en) * | 2019-05-28 | 2019-08-02 | 黑龙江贝特佳营养食品有限公司 | A kind of infant formula goat milk powder produced with degreasing goat milk powder |
| CN110169454A (en) * | 2019-05-10 | 2019-08-27 | 上海育博营养食品有限公司 | A kind of children's formula milk for being conducive to protect eyes and help brain intelligence development |
-
2020
- 2020-02-27 CN CN202010122634.XA patent/CN111011522A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040202765A1 (en) * | 2003-04-14 | 2004-10-14 | Mcmahon Robert J. | Compositions and methods of formulation for enteral formulas containing sialic acid |
| CN105746728A (en) * | 2016-03-14 | 2016-07-13 | 上海晨冠乳业有限公司 | Infant formula milk powder simulating breast milk and preparation method of infant formula milk powder |
| CN106578092A (en) * | 2016-12-21 | 2017-04-26 | 海普诺凯营养品有限公司 | Children milk powder and making method thereof |
| CN109287759A (en) * | 2018-11-21 | 2019-02-01 | 上海育博营养食品有限公司 | A kind of formula milk and production method helping child height development |
| CN110169454A (en) * | 2019-05-10 | 2019-08-27 | 上海育博营养食品有限公司 | A kind of children's formula milk for being conducive to protect eyes and help brain intelligence development |
| CN110074190A (en) * | 2019-05-28 | 2019-08-02 | 黑龙江贝特佳营养食品有限公司 | A kind of infant formula goat milk powder produced with degreasing goat milk powder |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113678898A (en) * | 2020-05-19 | 2021-11-23 | 培臻生物科技(上海)有限公司 | Milk powder beneficial to development and growth of children and preparation method thereof |
| CN111758782A (en) * | 2020-07-09 | 2020-10-13 | 安徽贝尔宝母婴用品有限公司 | Milk powder beneficial to improving immunity and preparation method thereof |
| CN111990461A (en) * | 2020-08-18 | 2020-11-27 | 北安宜品努卡乳业有限公司 | Mixed milk powder for enhancing immunity and preparation method thereof |
| CN112471259A (en) * | 2020-11-25 | 2021-03-12 | 中宁县黄河乳制品有限公司 | Formula milk powder for promoting growth of height of children and preparation method thereof |
| CN112471260A (en) * | 2020-11-25 | 2021-03-12 | 中宁县黄河乳制品有限公司 | Organic formula milk powder for improving human immunity and preparation method thereof |
| CN112715946A (en) * | 2021-01-08 | 2021-04-30 | 美蓓(无锡)营养科技有限公司 | Sialic acid children nutrition bag |
| CN112753777A (en) * | 2021-01-27 | 2021-05-07 | 培臻生物科技(上海)有限公司 | Milk powder for improving immunity and preparation method thereof |
| CN113796424A (en) * | 2021-07-05 | 2021-12-17 | 百跃羊乳(南宁)有限公司 | Anti-infection children fruit and vegetable flavor formula sheep milk powder and preparation method thereof |
| CN115191488A (en) * | 2022-05-13 | 2022-10-18 | 湖南袁氏农牧科技发展有限公司 | A kind of formula milk powder for improving immunity of children and preparation method thereof |
| CN116548608A (en) * | 2023-05-06 | 2023-08-08 | 北安宜品努卡乳业有限公司 | Full-nutrition formula powder for children and preparation method and application thereof |
| CN116548608B (en) * | 2023-05-06 | 2024-01-26 | 北安宜品努卡乳业有限公司 | Full-nutrition formula powder for children and preparation method and application thereof |
| CN117281177A (en) * | 2023-07-28 | 2023-12-26 | 至同(杭州)健康科技有限公司 | Nutrient for stimulating intrinsic resistance of people over 3 years old and preparation method thereof |
| CN118415241A (en) * | 2024-05-23 | 2024-08-02 | 馨辰生物(广东)有限公司 | Bovine colostrum body-enhancing composition, solid beverage and oral liquid beverage |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111011522A (en) | Children formula milk powder capable of improving immunity and preparation method thereof | |
| CN111264632A (en) | Children formula milk powder for promoting calcium growth and preparation method thereof | |
| EP2934189B1 (en) | Human milk oligosaccharides to ameliorate symptoms of stress | |
| CN107660620B (en) | Sheep-based oil microcapsule powder and preparation method thereof | |
| EP2708145B1 (en) | Nutritional compositions for use in methods for modulating corticosterone levels in psychologically stressed individuals | |
| CN107048122A (en) | A kind of hoveniae semoveniae semen health drink of energy relieving alcoholism and protecting liver and preparation method thereof | |
| CN113397164A (en) | Special medical full-nutrition formula food for improving immunity and preparation method thereof | |
| CN110301629A (en) | A kind of full nutrient solid beverage of tumor patient and preparation method thereof | |
| CN111067104A (en) | Composite probiotic infant formula milk powder and preparation method thereof | |
| US20210361616A1 (en) | Ameliorating agent for female-specific physical and/or mental unpleasant symptom | |
| CN111264633A (en) | Children formula milk powder beneficial to intestinal health and preparation method thereof | |
| CN115708530A (en) | Pregnant and lying-in woman formula milk powder capable of promoting digestive comfort and stabilizing blood sugar and preparation method thereof | |
| CN111616221A (en) | Milk powder for improving memory and relieving pressure and preparation method thereof | |
| CN109123660A (en) | A kind of walnut lactalbumin composite powder and preparation method thereof for maternal nutritional product | |
| CN114424825B (en) | Quintuple fat-reducing composition and preparation method and application thereof | |
| CN111587923A (en) | An infant formula containing sialic acid and its preparation method | |
| CN111296585A (en) | Formula milk powder for promoting height increase and brain development of children and preparation method thereof | |
| CN110074189A (en) | A kind of infant's diatery supplement and preparation method thereof adding human milk oligosaccharides | |
| CN118805891B (en) | Composition for inhibiting fat absorption and controlling body weight and preparation method thereof | |
| CN116548608B (en) | Full-nutrition formula powder for children and preparation method and application thereof | |
| CN113170844A (en) | Vegetable and fruit fiber nutritional beverage | |
| CN103082003A (en) | Dietary supplement having immunoloregulation effect | |
| CN113545464A (en) | A kind of starch jelly for calming the nerves and improving intelligence and preparation method thereof | |
| CN107996934A (en) | A kind of D ribose bamboo-leaves flavones solid beverage | |
| CN112715673A (en) | Children formula milk powder and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 266323 merchants Road, dazhuge Industrial Park, Zhangying Town, Jiaozhou City, Qingdao City, Shandong Province Applicant after: Qingdao ouenbei nutritional food Co.,Ltd. Address before: 266323 merchants Road, dazhuge Industrial Park, Zhangying Town, Jiaozhou City, Qingdao City, Shandong Province Applicant before: Qingdao Suokang Food Co.,Ltd. |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200417 |